1/8
08:02 am
ctnm
Contineum Therapeutics (NASDAQ:CTNM) had its "equal weight" rating reaffirmed by analysts at Morgan Stanley. They now have a $14.00 price target on the stock, down previously from $23.00.
Low
Report
Contineum Therapeutics (NASDAQ:CTNM) had its "equal weight" rating reaffirmed by analysts at Morgan Stanley. They now have a $14.00 price target on the stock, down previously from $23.00.
1/8
08:02 am
ctnm
Contineum Therapeutics (NASDAQ:CTNM) had its "equal weight" rating reaffirmed by analysts at Morgan Stanley. They now have a $14.00 price target on the stock, down previously from $23.00.
Low
Report
Contineum Therapeutics (NASDAQ:CTNM) had its "equal weight" rating reaffirmed by analysts at Morgan Stanley. They now have a $14.00 price target on the stock, down previously from $23.00.
1/8
07:18 am
ctnm
Rating for CTNM
Low
Report
Rating for CTNM
1/8
07:18 am
ctnm
Rating for CTNM
Low
Report
Rating for CTNM
1/8
06:19 am
ctnm
Contineum downgraded to Equal Weight from Overweight at Morgan Stanley
Low
Report
Contineum downgraded to Equal Weight from Overweight at Morgan Stanley
1/8
06:19 am
ctnm
Contineum downgraded to Equal Weight from Overweight at Morgan Stanley
Low
Report
Contineum downgraded to Equal Weight from Overweight at Morgan Stanley
11/24
09:40 am
ctnm
Rating for CTNM
Low
Report
Rating for CTNM
11/24
09:40 am
ctnm
Rating for CTNM
Low
Report
Rating for CTNM
11/21
09:33 am
ctnm
Rating for CTNM
Low
Report
Rating for CTNM
11/21
09:33 am
ctnm
Rating for CTNM
Low
Report
Rating for CTNM
11/13
09:53 am
ctnm
Contineum Therapeutics (NASDAQ:CTNM) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $22.00 price target on the stock.
Medium
Report
Contineum Therapeutics (NASDAQ:CTNM) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $22.00 price target on the stock.